Expanded immunisation program adds cervical cancer vaccine
The District Health Authority (DHA) Rawalpindi has announced a significant expansion of Pakistan’s national immunisation program. Cervical cancer has been added as the thirteenth disease targeted by the drive, joining a list that already includes tuberculosis, diphtheria, measles, pertussis, tetanus, polio, pneumonia, diarrhoea, typhoid, and hepatitis B among others. This enhancement marks a shift toward broader protection against preventable illnesses through routine vaccination.
HPV vaccination to begin in February 2026
Starting February next year, the HPV vaccination will be administered exclusively to nine-year-old girls as part of a year‑round expanded campaign. The DHA has outlined that from February 2026 onward, the focus will remain on this age group to ensure early and lasting protection against cervical cancer.
Recent vaccination drive results and future plans
Officials reported strong performance from the recent vaccination drive held from September 15 to 27 this year. The campaign targeted girls aged nine to 14 and achieved 94 percent of its target. The success is being cited as a precursor to the more focused, ongoing program beginning in February 2026.
Why nine-year-olds? Goals and expected impact
Health authorities emphasise that vaccinating at age nine provides timely and durable immunity, aligning with international best practices for HPV immunisation. The shift toward a single age group aims to streamline delivery, improve uptake, and maximize long-term protection for girls against cervical cancer.
Local and national health implications
With cervical cancer added to the immunisation schedule, the Rawalpindi DHA is expanding preventive measures and reinforcing public health infrastructure. The move is expected to reduce future cervical cancer incidence and mortality, while contributing to broader national efforts to safeguard women’s health through routine vaccination.
What comes next for residents
Parents and guardians should stay informed about vaccination dates and local clinics offering the HPV vaccine. Health workers will provide details on eligibility, consent, and potential side effects, as well as ongoing reminders for the year‑round program. The DHA has underscored its commitment to sustaining high coverage and monitoring vaccine safety and effectiveness.
Conclusion
The inclusion of cervical cancer vaccination within Pakistan’s national immunisation program, and the planned focus on nine-year-old girls from February 2026, represents a major step in preventive health. By prioritising early protection against HPV, Rawalpindi aims to secure healthier futures for its young residents and contribute to global efforts against cervical cancer.
